What are the recent financial highlights of GLAXOSMITHKLINE PHARMA LT?

GLAXOSMITHKLINE PHARMA LT recently reported a total revenue of ₹3,704.64 Cr and a net profit margin of 23.19%. These metrics reflect the company’s consistent financial performance.

What is the dividend yield of GLAXOSMITHKLINE PHARMA LT?

GLAXOSMITHKLINE PHARMA LT offers a dividend yield of 1.17%, with a dividend rate of ₹32.0 per share.

What are the key financial metrics of GLAXOSMITHKLINE PHARMA LT?

Key financial metrics include a trailing P/E ratio of 50.82577, forward P/E of 44.48791, book value of ₹97.182, price-to-book ratio of 26.505424, and a market capitalization of ₹436.36 billion.

What does GLAXOSMITHKLINE PHARMA LT do?

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Loading...

₹ 0 0.00%

Loading... BSE: Loding... NSE: Glaxo

About

Loading... ^[1]

Website BSE NSE

Market Cap ₹ 0 Cr.
Current Price ₹ 0
High / Low ₹ 0 / 0
Stock P/E
Dividend Yield 0 %
ROE 0 %
EPS 0
P/B Ratio 0
Net Profit Margin 0 %
Debt to Equity 0
ROCE 0 %
Interest Coverage 0 %

Stock News - Glaxo

Latest updates related to Glaxo

Sr No.	Title	Sentiment
1	GlaxoSmithKline Pharma Q3FY25: Net profit rises 400% to Rs 228.58 crore Business Standard	🔄
2	Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue? Yahoo Finance	🔄
3	GlaxoSmithKline Pharmaceuticals shares hit 20% upper circuit as profit jumps fivefold in Q3FY25 Mint	🔄
4	GlaxoSmithKline Adjusts Market Evaluation Amidst Resilient Performance and Growth Challenges MarketsMojo	🔄
5	GlaxoSmithKline seen as favourite to buy Pfizer's consumer healthcare unit after Reckitt Benckiser ends interest FirstWord Pharma	🔄
6	India's GlaxoSmithKline Pharma reports higher profit on strong demand for respiratory drugs Reuters	🔄
7	GlaxoSmithKline Pharma to enter oncology market, launch adult vax The Times of India	🔄
8	GlaxoSmithKline Consolidated December 2024 Net Sales at Rs 949.42 crore, up 17.9% Y-o-Y Moneycontrol	🔄
9	I-Sec upgrades GlaxoSmithKline Pharma to Add, lowers target price to Rs 2,250 The Economic Times	🔄
10	GlaxoSmithKline hits 20% upper circuit on posting 400% jump in Q3 PAT Business Standard	🔄

Peer Comparison

Macro Industry: Loading.. | Sector: Loading.. | Industry: Loading.. | Basic Industry: Loading..

Loading peers table...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Loading data...

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Loading Profit & Loss data...

Compounded Sales Growth
10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth
10 Years:
5 Years:
3 Years:
TTM:

Stock Price CAGR
10 Years:
5 Years:
3 Years:
1 Year:

Return on Equity
10 Years:
5 Years:
3 Years:
Last Year:

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Shareholding Pattern

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Loading...

Loading...

Stock News - Glaxo

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Delivery Data

Insider Data

Technical Data

Static Application Security Testing

Documents

Announcements

Annual reports

Credit ratings

Concalls

Explore More Stocks